ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,969.34
0.35%
US Tech 100
20,266.40
0.33%
다우존스 지수
44,296.51
0.97%
Bitcoin
98,659.88
-0.37%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Aclaris Therapeutics Inc (ACRS)

  7. Aclaris Therapeutics Inc (ACRS) 뉴스

ACRS

Aclaris Therapeutics (ACRS)

Aclaris Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ACRS
일자시간출처헤드라인심볼기업
2024/11/2306:00Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ACRSAclaris Therapeutics Inc
2024/11/2206:51Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ACRSAclaris Therapeutics Inc
2024/11/2106:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
2024/11/2006:05AllPennyStocks.comThis Healthcare Stock Soared Following Exclusive License Agreement AnnouncementNASDAQ:ACRSAclaris Therapeutics Inc
2024/11/1906:20Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
2024/11/1822:50PR Newswire (US)Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology AssetsNASDAQ:ACRSAclaris Therapeutics Inc
2024/11/1822:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
2024/11/1822:10GlobeNewswire Inc.Aclaris Therapeutics Announces $80 Million Private PlacementNASDAQ:ACRSAclaris Therapeutics Inc
2024/11/1822:10GlobeNewswire Inc.Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to PipelineNASDAQ:ACRSAclaris Therapeutics Inc
2024/11/0706:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRSAclaris Therapeutics Inc
2024/11/0621:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
2024/11/0621:00GlobeNewswire Inc.Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
2024/11/0606:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
2024/10/0405:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
2024/09/1720:00GlobeNewswire Inc.Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic DermatitisNASDAQ:ACRSAclaris Therapeutics Inc
2024/09/1020:00GlobeNewswire Inc.Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare ConferenceNASDAQ:ACRSAclaris Therapeutics Inc
2024/09/0508:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
2024/09/0506:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
2024/08/1405:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
2024/08/0720:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
2024/08/0720:00GlobeNewswire Inc.Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
2024/08/0605:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
2024/07/1705:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
2024/07/1705:01GlobeNewswire Inc.Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 MillionNASDAQ:ACRSAclaris Therapeutics Inc
2024/06/1105:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
2024/06/1105:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
2024/06/1105:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
2024/06/0805:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
2024/06/0620:00GlobeNewswire Inc.Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ACRSAclaris Therapeutics Inc
2024/06/0505:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
 검색 관련기사 보기:NASDAQ:ACRS

최근 히스토리

AMEX
SPY
SPDR S&P 500
COIN
DOGEUSD
Dogecoin
USOTC
RHHBY
Roche (QX)
NYSE
DIS
Walt Disney
NYSE
NKE
Nike
FX
USDGBP
US Dollar vs Sterling
COIN
AVAXUSD
Avalanche
NYSE
KO
Coca Cola
NASDAQ
GOOGL
Alphabet
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USI
USTECH100
US Tech 100
COIN
XRPUSD
Ripple
PM
XAUUSD
Gold vs US Dollar
COIN
ETHUSD
Ethereum
NYSE
CVX
Chevron
CCOM
US500
US 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유